CASP3 and lung cancer: Additionally, it has been reported that both paclitaxel and cisplatin can activate the caspase-3/GSDME pathway, shifting the cell death process from apoptosis to pyroptosis, thus suppressing lung cancer cell proliferation (Zhang et al., 2019).